U.S. markets closed

Generex Biotechnology Corporation (GNBT)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.2650-0.0108 (-3.90%)
At close: 3:30PM EDT

Generex Biotechnology Corporation

10102 USA Today Way
Suite 200
Miramar, FL 33025
United States
416 364 2551
http://generex.com/index.html

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees15

Key Executives

NameTitlePayExercisedYear Born
Mr. Joseph MoscatoCEO, Pres & Chairman623.08kN/A1964
Mr. Mark CorraoCFO & Treasurer10kN/A1958
Mr. Terry R. ThompsonChief Operating Officer566.44kN/A1958
Mr. Andrew RoChief Investment Officer, Sr. VP of Investments & Director18.88kN/A1971
Mr. Anthony S. Crisci CPA, Esq.Chief Legal Officer424.83kN/A1970
Mr. Anthony J. DolisiChief Commercial OfficerN/AN/A1965
Dr. Jason Bradley TerrellChief Scientific Officer & Chief Medical OfficerN/AN/A1980
Ms. Michelle StarrChief Marketing OfficerN/AN/AN/A
Mr. Richard D. PurcellExec. VP of Research & Drug Devel.N/AN/A1961
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Generex Biotechnology Corporation, through its subsidiaries, engages in the administration of formulations of large molecule drugs to the oral cavity using a hand-held aerosol applicator in Canada and the United States. It offers Generex Oral-lyn, an oral insulin product. The company is also developing AE37, a synthetic peptide vaccine, which has completed Phase IIb clinical trial to stimulate a potent and specific immune response against tumors expressing the HER-2/neu oncogene in patients with breast cancer and prostate cancer. In addition, it develops, manufactures, and distributes rapid point-of-care in-vitro medical diagnostics for infectious diseases, such as human immunodeficiency virus, tuberculosis, malaria, hepatitis B, hepatitis C, syphilis, and others; and test kits and cassettes for testing infectious diseases, as well as Excellagen, a wound conforming gel. Further, the company is developing immunotherapeutic products and vaccines; and extracellular matrix hydrogel solution, a tissue engineered therapy for the treatment of Ulcerative Colitis. Additionally, it manufactures and sells foot and ankle surgical kits that include plates, screws, and tools; and distributes surgical supplies, orthopedic implants, artificial joints, and biologics, medical devices, and regenerative medicine products. It also serves as the general partner of the Management Services Organization. Generex Biotechnology Corporation was founded in 1983 and is headquartered in Miramar, Florida.

Corporate Governance

Generex Biotechnology Corporation’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.